Found 324 clinical trials
Stand Up to Cancer Consortium Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients With BRAF Wild-Type (BRAFwt) Metastatic Melanoma (015-104)
Stand Up to Cancer Consortium Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients With BRAF Wild-Type (BRAFwt) Metastatic Melanoma (015-104)
- 456 views
- 23 Nov, 2020
- 1 location
Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma
The study aims to evaluate the safety and preliminary efficacy of the combination of cabozantinib and pembrolizumab in advanced melanoma
- 0 views
- 04 Oct, 2022
- 1 location
ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma
With the introduction of checkpoint inhibitors substantial improvements have been made in the treatment of malignant melanoma (MM). Despite this still a a subset of patients, approximately 50 %, experience no response to therapy. One of the strategies to overcome these obstacles have been ACT with tumour infiltrating lymphocytes (TILs). …
- 0 views
- 25 Sep, 2021
- 1 location
A Study of Toripalimab or Combining With Temozolomide iv in the Treatment of Advanced/Metastatic Malignant Melanoma
This study evaluate toripalimab or combining with temozolomide for injection in the treatment of advanced/metastatic malignant melanoma. Participants in arm A receive toripalimab, in arm B
- 2 views
- 24 May, 2021
- 1 location
An Open Label, Phase 1, First-in-human, Study to Evaluate Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics and Tumor Response Profile of Schlafen12 Complex Inducer (SLFN12 ci) BAY 2666605 in Participants With Metastatic Melanoma and Other Advanced Solid Tumors.
Researchers are looking for a better way to treat people who have advanced cancer. In this study researchers want to learn more about a new substance called BAY2666605. BAY2666605 triggers the formation of a complex of two proteins called SLFN12 and PDE3A. This complex drive cancer cells into cell death …
- 6 views
- 14 Oct, 2022
- 3 locations
A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
Approximately 40 participants with locally advanced or metastatic melanoma will be enrolled in 20 sites in the United States into 1 of the following 2 arms: Primary resistance to initial
- 0 views
- 23 Oct, 2022
- 13 locations
Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
with anti-PD-1/PD-L1 refractory metastatic cutaneous melanoma.
- 0 views
- 27 Jun, 2022
- 1 location
Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
unresectable or metastatic melanoma. The study team wants to know the effectiveness of these drugs together in treating cancer than if each study drug was given by itself.
- 96 views
- 14 Apr, 2022
- 1 location
Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma
with metastatic melanoma that failed immunotherapy.Tumor-infiltrating lymphocytes will be expanded from resected melanoma samples from the patient and expanded TILs will be transferred to the patient
- 0 views
- 14 Aug, 2021
- 1 location
A Phase 1/2 Study of ASP1570 in Participants With Locally Advanced or Metastatic Solid Tumors
Part 1 without getting major medical problems. Some groups of people will have specific advanced tumors. These include tumors from metastatic melanoma or non-small cell lung cancer (NSCLC for short
- 2 views
- 21 Oct, 2022
- 10 locations